Novo’s Once-Daily Sickle Cell Pill Hits Milestone. A Smaller Rival Is Sinking 24%.
Barrons
—
Novo Nordisk says it plans to apply for regulatory approval of its sickle cell disease, etavopivat, in the second half of 2026.